01—Abstract
Summary
Summary of the 10-K filed February 29, 2008. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company's 2008 10-K filing for the fiscal year ended December 30, 2007, highlights a year of substantial growth, with worldwide sales increasing by 19% to $18.63 billiona.
This growth was largely fueled by the acquisition of ICOS and strong performance from key products like Cymbalta, Zyprexa, Alimta, Gemzar, and Humalog. The company demonstrated a continued commitment to research and development, investing 19%b of its sales in R&D activities, signaling a focus on future innovation. Despite robust sales growth, the company faced increased operating expenses, partly due to the ICOS acquisition and increased marketing efforts.
Net income and earnings per share saw a 11% increase, reaching $2.95 billionc and $2.71 per share, respectively. However, the company also reported significant special charges and in-process R&D expenses related to acquisitions and strategic decisions. Investors should note the ongoing legal and regulatory matters, particularly those concerning Zyprexa, which have led to substantial settlement charges, and the potential impact of patent expirations in the coming years.
02—Key points
Key Highlights
- Worldwide sales grew by 19% to $18.63 billion in 2007, driven by strong performance of key products and the acquisition of ICOS.
- Research and Development (R&D) investment remained a significant priority, with the company investing 19% of its sales, totaling $3.49 billion in 2007.
- Net income increased by 11% to $2.95 billion, and diluted earnings per share rose to $2.71.
- The acquisition of ICOS in January 2007 for approximately $2.3 billion significantly contributed to the growth and brought the full value of Cialis under Lilly's control.
- The company faced substantial legal and regulatory challenges, including ongoing investigations and product liability litigation, particularly related to Zyprexa, resulting in significant settlement charges.
- Major product sales included Zyprexa ($4.76 billion), Cymbalta ($2.10 billion), Gemzar ($1.59 billion), Humalog ($1.47 billion), and Cialis ($1.14 billion), with Cymbalta showing particularly strong growth.
- The company increased its quarterly dividend by 10.6% and has a history of consistent dividend increases, marking its 40th consecutive year of increases.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2007filed February 29, 200805—Questions
Frequently Asked Questions
What were the main drivers of Eli Lilly's sales growth in 2007?
Eli Lilly's sales growth in 2007 was primarily driven by the acquisition of ICOS Corporation, which brought the Cialis product line fully into Lilly's portfolio, and strong volume increases from key products such as Cymbalta, Zyprexa, Alimta, Gemzar, and Humalog. The company also benefited from favorable foreign exchange rates.
What are the significant legal and regulatory issues facing the company?
The company is involved in several significant legal and regulatory matters. These include ongoing investigations into its U.S. sales and marketing practices, particularly concerning Zyprexa, Prozac, and Evista. Additionally, there is substantial product liability litigation related to Zyprexa, alleging side effects like diabetes and high blood-glucose levels, which has led to significant settlement charges. The company is also facing patent challenges in various countries for its key products, including Zyprexa.
How did the company's R&D investment in 2007 compare to previous years, and what is its outlook?
Eli Lilly continued to make significant investments in Research and Development, spending $3.49 billion in 2007, which represented 19% of its sales. This reflects a consistent commitment to innovation, with R&D expenses increasing from $3.13 billion in 2006 and $3.03 billion in 2005. The company expects R&D expenses to grow in the high-single to low-double digits in 2008.
What is the company's financial health and outlook for 2008?
As of December 31, 2007, Eli Lilly had $4.83 billion in cash, cash equivalents, and short-term investments. The company expects earnings per share for 2008 to be in the range of $3.80 to $3.95 and anticipates sales to grow in the mid-to high-single digits, driven by key products. The company stated that cash generated from operations, along with available cash, should be sufficient to fund its needs, and its debt ratings remain strong.
06—Continue